163 related articles for article (PubMed ID: 26935789)
1. Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells.
Zhou W; Chen X; He K; Xiao J; Duan X; Huang R; Xia Z; He J; Zhang J; Xiang G
Oncol Rep; 2016 May; 35(5):2535-42. PubMed ID: 26935789
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma - cell line findings.
Sriraksa R; Limpaiboon T
Asian Pac J Cancer Prev; 2013; 14(4):2503-8. PubMed ID: 23725164
[TBL] [Abstract][Full Text] [Related]
3. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
4. Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro.
Fan S; Ge Y; Liu J; Liu H; Yan R; Gao T; Fan X; Xiao Z; An G
J Clin Lab Anal; 2021 Oct; 35(10):e23986. PubMed ID: 34462984
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum.
Brosch G; Ransom R; Lechner T; Walton JD; Loidl P
Plant Cell; 1995 Nov; 7(11):1941-50. PubMed ID: 8535144
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
Fraveto A; Cardinale V; Bragazzi MC; Giuliante F; De Rose AM; Grazi GL; Napoletano C; Semeraro R; Lustri AM; Costantini D; Nevi L; Di Matteo S; Renzi A; Carpino G; Gaudio E; Alvaro D
PLoS One; 2015; 10(11):e0142124. PubMed ID: 26571380
[TBL] [Abstract][Full Text] [Related]
7. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.
Jung DE; Park SB; Kim K; Kim C; Song SY
Sci Rep; 2017 Sep; 7(1):10921. PubMed ID: 28883618
[TBL] [Abstract][Full Text] [Related]
8. Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma.
Koprowski S; Sokolowski K; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
J Surg Res; 2015 Oct; 198(2):434-40. PubMed ID: 25890434
[TBL] [Abstract][Full Text] [Related]
9. Characterization of inhibitor-resistant histone deacetylase activity in plant-pathogenic fungi.
Baidyaroy D; Brosch G; Graessle S; Trojer P; Walton JD
Eukaryot Cell; 2002 Aug; 1(4):538-47. PubMed ID: 12456002
[TBL] [Abstract][Full Text] [Related]
10. Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro.
Deubzer HE; Ehemann V; Kulozik AE; Westermann F; Savelyeva L; Kopp-Schneider A; Riester D; Schwab M; Witt O
Cancer Lett; 2008 Jun; 264(1):21-8. PubMed ID: 18262346
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.
Yin Y; Zhang M; Dorfman RG; Li Y; Zhao Z; Pan Y; Zhou Q; Huang S; Zhao S; Yao Y; Zou X
Cell Death Dis; 2017 Jun; 8(6):e2856. PubMed ID: 28569784
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Baradari V; Höpfner M; Huether A; Schuppan D; Scherübl H
World J Gastroenterol; 2007 Sep; 13(33):4458-66. PubMed ID: 17724801
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells.
Joung KE; Kim DK; Sheen YY
Arch Pharm Res; 2004 Jun; 27(6):640-5. PubMed ID: 15283467
[TBL] [Abstract][Full Text] [Related]
15. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells.
Deubzer HE; Ehemann V; Westermann F; Heinrich R; Mechtersheimer G; Kulozik AE; Schwab M; Witt O
Int J Cancer; 2008 Apr; 122(8):1891-900. PubMed ID: 18074352
[TBL] [Abstract][Full Text] [Related]
17. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
[TBL] [Abstract][Full Text] [Related]
18. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
[No Abstract] [Full Text] [Related]
19. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
20. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T
Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
